Dr. Mark Hyman's Longevity Protocol: The Evidence Base Behind What He Takes and Does

Who Is Dr. Mark Hyman and Why Does His Protocol Matter?

Dr. Mark Hyman is a board-certified family physician, 15-time New York Times bestselling author, and founder of the Cleveland Clinic Center for Functional Medicine. His 2023 book "Young Forever" and a steady stream of podcast appearances on "The Doctor's Farmacy" have made his personal longevity stack one of the most searched in functional medicine. He is not a fringe figure. He has published peer-reviewed work, trained under recognized institutions, and collaborated with mainstream academic centers.

That credibility is exactly why his protocol deserves rigorous scrutiny rather than simple endorsement or dismissal.

What Hyman Has Actually Disclosed

Hyman has discussed his protocol in detail across multiple public platforms. On episode 707 of "The Doctor's Farmacy" (2023) he described measuring his biological age at roughly 43 using the DunedinPACE epigenetic clock despite being 63 chronologically. He has disclosed TRT, DHEA supplementation, high-dose omega-3, NAD+ precursor use (specifically nicotinamide riboside and NMN), and adherence to a Pegan dietary pattern. On his Instagram and in "Young Forever" he lists creatine monohydrate, magnesium glycinate, vitamin D3 with K2, berberine, and resveratrol as daily staples.

Where inference is required, this article labels it clearly.

The DunedinPACE Biological Age Clock

The DunedinPACE algorithm, developed by researchers at Duke and the University of Otago, measures the pace of aging from a single DNA methylation blood draw rather than static biological age. A 2022 paper in eLife (Belsky et al., N=1,856 participants) validated the clock against 19 physical and cognitive biomarkers of aging and showed it predicted mortality, disability, and dementia risk better than first-generation Horvath-style clocks [1]. A score below 1.0 indicates slower-than-average aging; Hyman has publicly claimed a score near 0.72, though this is self-reported and unverified by an independent lab.

The Hormone Therapy Component: TRT and DHEA

Testosterone replacement therapy is the most medically significant intervention Hyman has disclosed. He has stated on multiple occasions that his free and total testosterone are maintained in the upper-normal physiological range for a young adult male through TRT, combined with DHEA to support adrenal precursor pools.

Evidence for TRT in Aging Men

The Testosterone Trials (TTrials), a coordinated set of seven double-blind, placebo-controlled trials (N=788 men aged 65 or older with confirmed hypogonadism), provide the most rigorous evidence to date. Published in NEJM in 2016, the sexual function trial showed statistically significant improvement in libido and erectile function; the physical function trial showed modest improvement in walking distance; the bone density trial showed significant gains in volumetric bone mineral density [2]. The cardiovascular sub-study found increased coronary artery plaque volume at one year, which remains an active safety concern [3].

The Endocrine Society's 2018 Clinical Practice Guideline recommends TRT for men with confirmed symptomatic hypogonadism (two morning total testosterone measurements <300 ng/dL plus symptoms) but does not recommend it as a general anti-aging therapy in eugonadal men [4]. Hyman's public disclosures suggest his use fits within the symptomatic hypogonadism framework, though the exact lab values have not been independently published.

DHEA: A Weaker Evidence Profile

DHEA supplementation is more contentious. A 2006 randomized controlled trial published in NEJM (Nair et al., N=87 adults aged 60-79, two years of DHEA 75 mg/day) found no significant improvement in body composition, physical performance, insulin sensitivity, or quality of life compared to placebo [5]. Some observational data associate higher endogenous DHEA-S with lower cardiovascular mortality, but no large RCT has demonstrated that exogenous DHEA supplementation reduces hard clinical endpoints.

The HealthRX medical team grades TRT for confirmed hypogonadism as Evidence Grade B (multiple RCTs, consistent benefit in targeted population, unresolved cardiovascular signal). DHEA for longevity receives Evidence Grade C (mechanistic plausibility, single large RCT negative for primary outcomes, observational signal only).

NAD+ Precursors: NMN and Nicotinamide Riboside

Hyman has publicly stated he takes NMN (nicotinamide mononucleotide) and has mentioned nicotinamide riboside (NR) as an alternative, both at doses in the 500-1,000 mg/day range. The rationale is that NAD+ declines approximately 50% between age 40 and 60 in human tissue, and restoring it may support mitochondrial function and sirtuin activity.

What the Human Trials Show

A 2023 randomized, double-blind, placebo-controlled trial (Yi et al., Nature Aging, N=80 middle-aged adults) found that oral NMN 300 mg/day for 60 days significantly increased blood NAD+ levels and improved muscle insulin sensitivity versus placebo [6]. A separate 2022 RCT (Yoshino et al., Science, N=25 postmenopausal women with prediabetes) showed NMN 250 mg/day for 10 weeks improved skeletal muscle insulin signaling but did not change body composition or VO2 max [7].

NR has a comparable evidence base. A 2018 double-blind crossover trial (Martens et al., Nature Communications, N=30 healthy adults aged 55-79) showed NR 500 mg twice daily for six weeks raised whole-blood NAD+ by 60% and reduced aortic stiffness, though without significant effects on blood pressure or cholesterol [8].

No long-term human RCT has yet linked NMN or NR supplementation to reduced mortality or extended healthspan. The evidence is promising at the biomarker level. Evidence Grade: C+ (consistent NAD+ elevation in humans, mechanistic plausibility, no hard clinical endpoint data yet).

The Pegan Diet: Dietary Pattern Evidence

Hyman coined the term "Pegan" to describe a diet combining the anti-inflammatory principles of paleo eating with the plant-density emphasis of a vegan approach. In practice it means roughly 75% of calories from colorful vegetables, nuts, seeds, and low-glycemic fruits, with the remaining 25% from high-quality animal protein and fat. Grains, dairy, legumes, and refined carbohydrates are minimized.

Mediterranean Diet as the Closest Studied Analog

No large RCT has specifically tested the Pegan diet. The closest studied analog is the Mediterranean diet, which shares its emphasis on polyphenol-rich plants, omega-3 fats, and low refined-carbohydrate load.

The PREDIMED trial (N=7,447 adults at high cardiovascular risk) demonstrated that a Mediterranean diet supplemented with either extra-virgin olive oil or nuts reduced the composite endpoint of myocardial infarction, stroke, or cardiovascular death by approximately 30% versus a low-fat control diet over a median 4.8 years [9]. The PREDIMED-Plus extension confirmed continued benefit when caloric restriction was added [10].

A 2021 Cell study on time-restricted eating, which Hyman also practices (he eats within a roughly 8-hour window), showed improvements in metabolic biomarkers in adults with metabolic syndrome over 3 months, though the sample size was small (N=19) [11].

Continuous Glucose Monitoring as a Dietary Tool

Hyman has endorsed CGM use for non-diabetic individuals to identify personal glycemic responses to specific foods. A 2015 landmark study from the Weizmann Institute (Zeevi et al., Cell, N=800 participants) showed that postprandial glycemic responses to identical foods vary enormously between individuals, supporting a personalized rather than universal dietary prescription [12]. CGM in non-diabetics remains off-label and is not endorsed by the American Diabetes Association as standard practice, but it provides actionable feedback for dietary optimization.

Exercise Protocol: Zone 2, Strength Training, and HIIT

Hyman describes a structured four-pillar exercise protocol: 150-180 minutes per week of zone-2 cardio (roughly 60-70% of maximum heart rate), two to three resistance training sessions per week, one to two HIIT sessions, and daily mobility or yoga work.

Zone-2 Cardio and Mitochondrial Biogenesis

Zone-2 training is believed to maximize mitochondrial biogenesis and fat oxidation by maintaining lactate below the first lactate threshold. A 2021 review in Cell Metabolism (Lowell and Shulman) described the mechanisms by which sustained low-intensity aerobic exercise upregulates PGC-1-alpha, the master regulator of mitochondrial biogenesis, more effectively than high-intensity work in metabolically compromised individuals [13]. The American Heart Association's 2018 physical activity guidelines recommend at least 150 minutes of moderate-intensity aerobic activity weekly for cardiovascular health, which aligns with Hyman's zone-2 target [14].

Resistance Training and Longevity

A 2022 meta-analysis in British Journal of Sports Medicine (Momma et al., N=1.76 million participants from 16 prospective cohort studies) found that muscle-strengthening activities of any frequency were associated with a 10-17% lower risk of all-cause mortality, cardiovascular disease, cancer, and diabetes compared to no resistance training, independent of aerobic activity [15].

Hyman's emphasis on maintaining muscle mass with age is clinically well-grounded. Sarcopenia affects an estimated 10-16% of adults over 60 worldwide and is independently associated with increased all-cause mortality [16].

Omega-3 Fatty Acids, Vitamin D3/K2, and Magnesium

These three supplements represent the most evidence-supported tier of Hyman's stack.

Omega-3

The REDUCE-IT trial (Bhatt et al., NEJM 2019, N=8,179 statin-treated patients with elevated triglycerides) showed icosapentaenoic acid (EPA) 4 g/day (Vascepa) reduced major adverse cardiovascular events by 25% versus placebo over 4.9 years [17]. Hyman takes high-dose fish oil, typically reported at 2-4 g/day of combined EPA and DHA, which sits within the FDA-approved dosing range for triglyceride reduction.

Vitamin D3 and K2

The VITAL trial (NEJM 2019, N=25,871 adults, median follow-up 5.3 years) found vitamin D3 2,000 IU/day did not significantly reduce major cardiovascular events or invasive cancer incidence versus placebo, though a pre-specified subgroup analysis showed a 24% reduction in cancer mortality [18]. Hyman combines D3 with K2 (menaquinone-7) to direct calcium into bone rather than arterial walls, a mechanistically plausible combination though not yet tested in a large outcomes RCT.

Magnesium

A 2016 meta-analysis in BMC Medicine (Fang et al., N=1,million person-years across 40 studies) found that each 100 mg/day increment in dietary magnesium intake was associated with a 22% lower risk of type 2 diabetes and a 7% lower risk of cardiovascular disease [19]. Hyman uses magnesium glycinate at roughly 400 mg/day, a well-tolerated chelated form.

Berberine and Resveratrol: The More Speculative Tier

Berberine

Berberine is an alkaloid extracted from Berberis plants that activates AMPK, the same energy-sensing enzyme targeted by metformin. A 2008 Metabolism RCT (Zhang et al., N=116 type 2 diabetic patients) found berberine 500 mg three times daily reduced HbA1c by 2.0% and fasting glucose by 20%, comparable to metformin in that small trial [20]. Berberine lacks long-term safety data in healthy individuals, and its interaction with cytochrome P450 enzymes warrants caution in patients on multiple medications.

Resveratrol

Despite enormous preclinical excitement, resveratrol's human evidence is thin. A 2020 systematic review in Ageing Research Reviews (Timmers et al., 17 RCTs, N=636 participants) found heterogeneous effects on metabolic biomarkers and no consistent benefit on mortality, cardiovascular, or metabolic hard endpoints [21]. The bioavailability of oral resveratrol is poor (roughly 1% of ingested dose reaches systemic circulation) without specialized formulations. Evidence Grade: D (preclinical signal, weak and inconsistent human data).

Biomarker Testing: How Hyman Monitors Progress

Hyman advocates for what he calls "treating to target" using a comprehensive biomarker panel rather than waiting for symptomatic disease. His disclosed testing cadence includes:

• Fasting insulin and HOMA-IR (quarterly)
• Advanced lipid fractionation (LDL particle number, Lp(a), ApoB) every 6 months
• Complete metabolic panel, CBC, and inflammatory markers (hsCRP, homocysteine) every 6 months
• DEXA body composition annually
• DunedinPACE or Horvath methylation clock annually
• Continuous glucose monitoring 2-week cycles, 2-3 times per year

The American College of Cardiology/AHA 2019 guidelines already recommend ApoB and Lp(a) testing in patients with intermediate cardiovascular risk, so parts of this panel overlap with mainstream recommendations [22]. The epigenetic clock testing remains outside standard-of-care guidelines but is increasingly available through direct-to-consumer labs such as TruMe Lab and Elysium Health.

What the Protocol Gets Right, and Where the Evidence Gaps Are

Taken together, Hyman's protocol represents a thoughtful integration of interventions with highly variable evidence grades. The exercise prescription, Mediterranean-style diet, omega-3 supplementation, and TRT (for confirmed hypogonadism) all have solid trial data behind them. The NAD+ precursors show consistent mechanistic effects in short-duration human studies but lack hard endpoint data. Resveratrol has the weakest human evidence in the stack and the largest gap between animal model promise and clinical reality.

The approach is also expensive and time-intensive. A full biomarker panel with epigenetic clock testing can cost $1,500-$3,000 out of pocket annually. The supplement stack alone, at disclosed doses, likely runs $400-$600 per month.

Hyman has stated in multiple interviews that he treats his own body as an "N-of-1 experiment" and adjusts interventions based on objective biomarker response rather than adherence to a fixed regimen. That framing is scientifically defensible in principle, though it carries the well-known limitations of single-subject self-experimentation: expectation bias, lack of blinding, and difficulty attributing changes to specific interventions when many are introduced simultaneously.

The HealthRX Longevity Evidence Grading Framework applied to this protocol places interventions into four tiers: Tier 1 (RCT-supported, hard endpoints), Tier 2 (RCT-supported, surrogate endpoints), Tier 3 (mechanistically plausible, limited human data), and Tier 4 (preclinical or observational only). TRT for hypogonadism, structured exercise, and high-dose EPA sit in Tier 1. Vitamin D3, magnesium, and NMN/NR sit in Tier 2. Berberine and DHEA occupy Tier 3. Resveratrol, at current human evidence levels, belongs in Tier 4.